HMPL-523 for Low Platelet Count
What You Need to Know Before You Apply
What is the purpose of this trial?
This is an open-label, multicenter study to evaluate the safety, tolerability, and efficacy of HMPL-523 in adult subjects with ITP.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial investigators.
What makes the drug HMPL-523 unique for treating low platelet count?
What data supports the effectiveness of the drug HMPL-523 for low platelet count?
Who Is on the Research Team?
William Schelman, MD, PhD
Principal Investigator
Hutchmed
Are You a Good Fit for This Trial?
Adults with immune thrombocytopenia (ITP), a condition where the blood doesn't clot well due to low platelet count, can join this trial. Specific details on who can or cannot participate are not provided here.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Subjects receive one of 3 dose levels of HMPL-523 to determine the recommended dose for the next stage
Dose Optimization
Subjects are randomized between 2 dose levels to understand exposure/efficacy/toxicity relationship
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- HMPL-523
HMPL-523 is already approved in China for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hutchmed
Lead Sponsor